Table 4 Clinicopathological parameters associated with long-term survival

Histotype

Age

50.41

57.39

0.01

 High-grade serous carcinoma

  Yes

3

39

Blood count

  No

21

126

0.22

 Hemoglobin

11.43

11.07

0.36

 Low-grade serous carcinoma

 White blood cell count

8.87

9.93

0.58

  Yes

5

5

 Platelet count

321.17

378.84

0.02

  No

19

160

< 0.01

 Neutrophil

8.06

7.45

0.69

 Clear cell carcinoma

 Lymphocyte

1.23

1.42

0.92

  Yes

3

21

 Neutrophil to lymphocyte ratio

7.82

10.34

0.51

  No

21

144

0.98

 Mucinous carcinoma

Clotting profile

  Yes

2

8

 Prothrombin time

11.37

12.08

0.70

  No

22

157

0.48

 Activated partial thromboplastin time

35.90

31.35

0.38

 Endometrioid carcinoma

 International normalized ratio

1.08

2.24

0.72

  Yes

4

9

  No

20

156

0.04

Liver/renal function

 High grade

 Creatinine

66.00

64.59

0.80

  Yes

11

72

 Serum albumin

37.67

31.89

0.01

  No

9

30

0.17

 Alkaline phosphatase

82.08

78.57

0.83

 Alanine transaminase

23.83

21.99

0.82

ECOG performance status scale

 Total serum protein

76.58

69.53

0.01

 ECOG ≥ 3

1

17

 ECOG < 3

14

203

0.88

Tumor markers

 Carcinoembryonic antigen

2.833

36.380

0.84

Treatment received prior to ascites

 Cancer antigen 125

162.33

2232.22

0.39

 Chemotherapy*

  Yes

2

64

  No

16

173

0.14

Surgery

  Yes

11

119

  No

7

118

0.37

Treatment received after diagnosis

 Chemotherapy*

  Yes

16

176

  No

2

61

0.17

Radiotherapy

  Yes

1

4

  No

17

233

0.25

 Surgery

  Yes

10

45

  No

18

192

< 0.01